{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-052074","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.741380+00:00","generated_at":"2026-06-03T07:54:03.980069+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rezolute to present Phase 2 RIZE overnight hypoglycemia data at PES Annual Meeting","bullets":["Dr. Paul Thornton will present poster analyzing overnight hypoglycemia in congenital HI patients on May 4, 2024 at PES meeting.","Sub-analyses from Phase 2 RIZE study highlight RZ358 benefits during overnight fasting using CGM metrics.","Previously reported results showed up to ~90% reduction in hypoglycemia events and time at top doses.","Phase 3 study of RZ358 for congenital hyperinsulinism is currently underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-052074","json":"https://secwatch.observer/filing/0001104659-24-052074.json","markdown":"https://secwatch.observer/filing/0001104659-24-052074.md","text":"https://secwatch.observer/filing/0001104659-24-052074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924052074/0001104659-24-052074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924052074/tm2412530d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:54:03.980069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}